A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkin's Lymphomas
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Oblimersen (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 31 Jul 2012 Actual patient number changed from 48 to 120 and lead trial investigator (Younes A) added as reported by ClinicalTrials.gov. (NCT01654952).
- 31 Jul 2012 Actual patient number changed from 48 to 120 and lead trial investigator (Younes A) added as reported by ClinicalTrials.gov. (NCT01654952).
- 17 Aug 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.